What is the appropriate evaluation and management for a patient with right bundle‑branch block who experiences palpitations, dizziness, and near‑syncope?

Immediate Electrophysiology Study (EPS) or Cardiac Monitoring Required

A patient with right bundle branch block (RBBB) experiencing palpitations, dizziness, and near-syncope requires urgent evaluation with electrophysiology study (EPS) as first-line, or implantable loop recorder (ILR) if EPS is unrevealing, to identify life-threatening intermittent AV block or ventricular arrhythmias. This presentation represents high-risk syncope that demands aggressive diagnostic workup to prevent sudden cardiac death.

Algorithmic Approach

Step 1: Initial Risk Stratification (Immediate)

• 12-lead ECG: Assess for bifascicular block (RBBB + left anterior/posterior fascicular block), PR interval prolongation, or alternating bundle branch block 1
• Echocardiogram: Evaluate for structural heart disease and left ventricular ejection fraction (LVEF) 1, 2
• Troponin and basic labs: Rule out acute coronary syndrome 3

Step 2: Determine Urgency Based on ECG Findings

Class I Indications for Immediate Permanent Pacing (No Further Testing Needed):

• Alternating bundle branch block (RBBB alternating with LBBB) = Class I recommendation for immediate pacemaker 1
• This pattern indicates unstable conduction in both bundles with imminent risk of complete heart block

Proceed to EPS if:

• Isolated RBBB with syncope/near-syncope
• Bifascicular block (RBBB + fascicular block) with symptoms
• RBBB with first-degree AV block and symptoms

Step 3: Electrophysiology Study Protocol

EPS is reasonable (Class IIa) when cardiac syncope is suspected with known substrate 1. The study should include:

1. Baseline HV interval measurement

   • HV ≥70 ms = Class I indication for permanent pacing 1
   • HV ≥60 ms predicts syncope recurrence (HR 3.58) 4

2. Incremental atrial pacing to assess for infranodal block

   • Infranodal block at pacing rates <150 bpm = high-risk finding 5

3. Pharmacological challenge with procainamide or ajmaline

   • Induction of high-degree AV block is highly predictive (68% develop spontaneous AV block during follow-up) 6, 7
   • Positive predictive value: 80-87% 6

4. Programmed ventricular stimulation if structural heart disease present

   • Ventricular tachycardia inducible in 32-42% of BBB patients 6, 8
   • More common with LVEF <40% and prior MI 9, 8

Step 4: Management Based on EPS Results

If EPS shows HV ≥70 ms or infranodal block:

• Permanent pacemaker implantation (Class I) 1
• Pacemaker therapy suppresses syncopal recurrences in almost all patients 6

If inducible ventricular tachycardia:

• Consider ICD if LVEF ≤35% or high-risk features 10
• Antiarrhythmic therapy guided by EPS 8

If EPS negative or HV 60-69 ms:

• Implantable loop recorder (ILR) - Class I (European) or Class IIa (US) 11, 5
• ILR diagnostic yield: 34% in BBB patients with negative EPS 7
• Median time to diagnosis of paroxysmal AV block: 97 days 7
• Alternative: Consider empiric pacemaker (Class IIa) given high short-term risk of AV block 5

Critical Pitfalls to Avoid

1. Do not observe without monitoring: 18-19% of patients with negative EPS develop AV block within 30 months 6. This is unacceptably high risk given symptoms.

2. Do not assume reflex syncope: While vasodepressor mechanisms can cause syncope in BBB patients, the combination of palpitations + near-syncope strongly suggests arrhythmic etiology 1

3. Bifascicular block is highest risk: Bifascicular block has HR 4.16 for recurrent syncope 4. These patients warrant most aggressive evaluation.

4. Pacemaker alone may not prevent sudden death: Total mortality remains 28% at 40 months in BBB patients, often from ventricular arrhythmias rather than bradycardia 6. If structural heart disease present, evaluate for ICD candidacy.

5. Right BBB with QR pattern in V1: Consider pulmonary embolism in acute presentations 12

Nuances in Decision-Making

European vs US Guidelines Divergence: The European guidelines favor EPS more strongly (Class I for bifascicular block with syncope) while US guidelines give Class IIa 11. However, both agree on the fundamental approach: systematic evaluation to identify mechanism before treatment.

ILR vs Empiric Pacing Debate: European guidelines upgraded EPS-guided pacing to Class I based on the B4 study showing parsimonious pacemaker use with rare syncope recurrence 11. However, given that 25% of paced patients still had recurrence in some trials, and ILR shows only ~50% have final diagnosis of AV block 11, the choice depends on:

• Patient preference for device burden
• Cost considerations
• Tolerance for potential additional syncopal spell during monitoring

For this specific patient with palpitations + near-syncope: The palpitations suggest paroxysmal arrhythmia (either AV block or VT), making EPS the preferred initial strategy over ILR.